郁龔杰,孫東東,曾勇,高偉偉,陳思親,張建寧
?
阿托伐他汀對(duì)顱腦外傷后小膠質(zhì)細(xì)胞激活的影響
郁龔杰1,孫東東1,曾勇1,高偉偉1,陳思親2,張建寧1
摘要:目的觀察阿托伐他汀對(duì)顱腦損傷(TBI)后小膠質(zhì)細(xì)胞激活的影響。方法將60只C57/BL6小鼠隨機(jī)分為假手術(shù)組、生理鹽水組和阿托伐他汀組,各20只。生理鹽水組和阿托伐他汀組采用液壓打擊法制作TBI模型。假手術(shù)組不進(jìn)行液壓打擊。阿托伐他汀組打擊后1 h給予阿托伐他汀(每天1 mg/kg)灌胃,連續(xù)7 d。生理鹽水組給予等量生理鹽水灌胃。采用免疫組化法檢測(cè)造模后第1、3、7天創(chuàng)傷灶周圍小膠質(zhì)細(xì)胞特異性標(biāo)志物(Iba-1)的數(shù)量及第3天基質(zhì)金屬蛋白酶(MMP)-9水平;Western blot檢測(cè)炎癥因子腫瘤壞死因子(TNF)-α水平。結(jié)果造模后第1、3、7天,阿托伐他汀組小鼠創(chuàng)傷灶周圍Iba-1陽(yáng)性表達(dá)量較生理鹽水組均顯著降低(80.00±7.44 vs.118.40± 6.65,85.60±10.87 vs.189.00±7.51,69.40±5.54 vs.102.40±10.89,P<0.05)。TBI后第3天,阿托伐他汀組MMP-9陽(yáng)性表達(dá)量與生理鹽水組相比也顯著下降(86.80±8.40 vs.133.80±8.46,P<0.05);Western blot檢測(cè)發(fā)現(xiàn)阿托伐他汀組與生理鹽水組相比TNF-α表達(dá)下降(0.64±0.01 vs.0.97±0.02,P<0.05)。結(jié)論阿托伐他汀能減少小鼠TBI后小膠質(zhì)細(xì)胞的激活,減少炎癥因子的表達(dá),起到抗炎作用。
關(guān)鍵詞:顱腦損傷;小神經(jīng)膠質(zhì)細(xì)胞;基質(zhì)金屬蛋白酶9;腫瘤壞死因子α;阿托伐他汀
顱腦外傷(TBI)是神經(jīng)外科的常見(jiàn)病和多發(fā)病,具有較高的致死率和致殘率,是45歲以下青壯年的主要死因[1-2]。小膠質(zhì)細(xì)胞是中樞神經(jīng)最重要的固有免疫細(xì)胞和主要的效應(yīng)細(xì)胞,TBI發(fā)生后,腦內(nèi)的小膠質(zhì)細(xì)胞被激活來(lái)清除損傷的細(xì)胞和組織。但是小膠質(zhì)細(xì)胞過(guò)度激活后識(shí)別“自己”的能力減弱,在發(fā)揮“清道夫”作用的同時(shí)可將正常血腦屏障(BBB)組織一并損傷,其分泌的腫瘤壞死因子(TNF)-α誘導(dǎo)顱內(nèi)免疫炎癥反應(yīng),進(jìn)而促進(jìn)顱腦繼發(fā)性損傷的發(fā)生[3]。研究表明,阿托伐他汀屬于β-羥基-β-甲基戊二酰輔酶A還原酶抑制劑,具有抗氧化和抗炎作用,能減少繼發(fā)性血管損傷和血栓形成。本研究旨在觀察阿托伐他汀對(duì)TBI后小鼠創(chuàng)傷灶周圍小膠質(zhì)細(xì)胞激活的影響,探討其在TBI中的作用。
1.1主要儀器與試劑液壓沖擊裝置(美國(guó)NEWSUN公司,MODEL01-B)、小動(dòng)物立體定向固定架(天津市神經(jīng)病學(xué)研究所,TJNS-I)、數(shù)字存儲(chǔ)示波器(美國(guó)Tektronix,TDS2012)、小動(dòng)物呼吸機(jī)(TKR-200C型)等。10%水合氯醛(天津醫(yī)科大學(xué)總醫(yī)院藥劑科)、多聚甲醛(武漢博士德公司)、阿托伐他?。ê贾菽硸|公司)。小膠質(zhì)細(xì)胞特異性標(biāo)志物(Iba-1,日本wako公司,0.01 mol/L,一抗稀釋液稀釋),基質(zhì)金屬蛋白酶-9(MMP-9,0.01 mol/L,一抗稀釋液稀釋)、TNF-α(美國(guó)Abcam公司)、β-肌動(dòng)蛋白(β-actin,美國(guó)CST公司)及相應(yīng)二抗(山羊抗兔,中山金橋公司)。
1.2實(shí)驗(yàn)動(dòng)物及分組健康成年雄性C57/BL6小鼠60只,清潔級(jí),體質(zhì)量20~25 g,購(gòu)自中國(guó)軍事醫(yī)學(xué)科學(xué)研究院,安靜、溫暖、避強(qiáng)光環(huán)境中飼養(yǎng)48 h。按照簡(jiǎn)單隨機(jī)抽樣法將60只小鼠分為假手術(shù)組、生理鹽水組和阿托伐他汀組,各20只。
1.3動(dòng)物模型制作及處理采用McIntosh等[4]的方法制備液壓打擊TBI模型。選擇前囟點(diǎn)后方2 mm,矢狀縫右側(cè)2 mm作為圓心,用磨鉆磨出一個(gè)直徑為2 mm的骨孔。保證硬膜完好。小鼠液壓打擊壓力為1.620 8×105~1.823 4×105Pa,沖擊時(shí)程約為20 ms。假手術(shù)組小鼠僅行頭皮切開和磨開骨孔,不進(jìn)行液壓打擊。阿托伐他汀組在液壓打擊后1 h至第7天給予1 mg/(kg·d)阿托伐他汀灌胃,生理鹽水組同時(shí)給予等量生理鹽水灌胃。
1.4免疫組織化學(xué)法檢測(cè)腦組織中Iba-1和MMP-9的表達(dá)情況造模后各組隨機(jī)抽取5只小鼠,采用10%水合氯醛腹腔注射麻醉后,4%多聚甲醛心室灌注,開顱取腦,再用4%多聚甲醛磷酸緩沖液固定24 h,然后常規(guī)脫水,石蠟包埋,以創(chuàng)傷灶為中心制作切片,連續(xù)5張,厚5 μm。將切好的散片脫蠟;切片入枸櫞酸鹽緩沖液微波加熱進(jìn)行抗原修復(fù)30 min;切片置入3%H2O2中抑制內(nèi)源性過(guò)氧化物酶10 min,蒸餾水洗5 min;切片入3%牛血清白蛋白(BSA)室溫下封閉1 h;后直接以兔抗小鼠Iba-1單抗1∶500,兔抗小鼠MMP-9單抗1∶200,4℃孵育過(guò)夜;磷酸鹽緩沖液(PBS)洗3次,每次5 min;切片入1∶200生物素標(biāo)記的二抗(5%BSA稀釋)2 h;PBS洗3次,每次5 min;辣根過(guò)氧化物酶(HRP)-生物素偶聯(lián)的三抗室溫孵育1 h;二氨基聯(lián)苯胺(DAB)顯色,顯微鏡下控制顯色時(shí)間;蘇木素復(fù)染;脫水封片。以上所有試劑除一抗外均購(gòu)自北京中山生物制劑有限公司。各實(shí)驗(yàn)組每份標(biāo)本在光鏡下隨機(jī)采集目標(biāo)區(qū)域5個(gè)視野,計(jì)算陽(yáng)性細(xì)胞數(shù)。所有計(jì)量數(shù)據(jù)由2名非實(shí)驗(yàn)人員按照雙盲原則進(jìn)行檢測(cè)。
1.5Western blot檢測(cè)TNF-α液壓打擊后第3天,10%水合氯醛麻醉小鼠取腦,加入1 mL裂解液,組織粉碎,勻漿;離心,取上清液,采用二奎林甲酸(BCA)法測(cè)定蛋白濃度并定量;經(jīng)10%十二烷基硫酸鈉-聚丙烯酰胺凝膠電泳(SDSPAGE)并轉(zhuǎn)膜;5%脫脂奶粉封閉2 h;將膜與1∶1 000稀釋的TNF-α、β-actin,抗體4℃孵育過(guò)夜,室溫下與相應(yīng)二抗孵育2 h,增強(qiáng)型化學(xué)發(fā)光試劑(ECL)顯示。以β-actin為內(nèi)參對(duì)照,結(jié)果以TNF-α/β-actin的吸光度比值表示。
1.6統(tǒng)計(jì)學(xué)方法應(yīng)用SPSS 16.0統(tǒng)計(jì)軟件分析,數(shù)據(jù)以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,兩組樣本比較采用獨(dú)立樣本t檢驗(yàn),以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1創(chuàng)傷灶周圍小膠質(zhì)細(xì)胞計(jì)數(shù)結(jié)果液壓打擊后第1、3、7天免疫組織化學(xué)顯示阿托伐他汀組小鼠創(chuàng)傷灶周圍小膠質(zhì)細(xì)胞特異性標(biāo)志物Iba-1陽(yáng)性表達(dá)量與生理鹽水組比較顯著減少(P<0.05),見(jiàn)圖1。
Fig.1 Comparison of the positive cells of Iba-1at different time points between two groups圖1 小鼠TBI后創(chuàng)傷灶周圍Iba-1陽(yáng)性表達(dá)量比較
2.2MMP-9檢測(cè)結(jié)果外傷后第3天阿托伐他汀組小鼠MMP-9陽(yáng)性表達(dá)量較生理鹽水組小鼠顯著減少(86.80±8.40 vs.133.80±8.46,t=8.807,P<0.05),見(jiàn)圖2。
Fig.2 The MMP-9 expression at the 3rd day after TBI between two groups(IHC,×200)圖2 小鼠TBI后第3天創(chuàng)傷灶周圍MMP-9的表達(dá)量(IHC,×200)
2.3TNF-α檢測(cè)結(jié)果外傷后第3天阿托伐他汀組小鼠TNF-α與生理鹽水組相比降低明顯(0.64± 0.01 vs.0.97±0.02,t=8.701,P<0.05),見(jiàn)圖3。
Fig.3 Results of Western blot assay for TNF-α/β-actin at the 3rd day after TBI圖3 TBI后第3天Western blot檢測(cè)TNF-α結(jié)果
TBI分為原發(fā)性和繼發(fā)性腦損傷,TBI后的免疫炎癥反應(yīng)所致的BBB繼發(fā)性損傷是繼發(fā)性腦損傷發(fā)生的關(guān)鍵。原發(fā)性腦損傷發(fā)生于TBI后的瞬間,治療干預(yù)困難。繼發(fā)性腦損傷的發(fā)生發(fā)展過(guò)程相對(duì)較長(zhǎng),是臨床救治的重點(diǎn)[1-2,5]。小膠質(zhì)細(xì)胞在中樞神經(jīng)系統(tǒng)分布較廣,約占膠質(zhì)細(xì)胞的10%~20%。TBI后,小膠質(zhì)細(xì)胞被激活,其分泌的炎癥介質(zhì)TNF-α、白細(xì)胞介素(IL)-1等是促進(jìn)繼發(fā)性腦損傷發(fā)生的關(guān)鍵因素[3]。MMPs是一組同源的以無(wú)活性酶原形式分泌的鋅依賴性中性蛋白酶,在正常腦組織中發(fā)揮重要的作用,比如神經(jīng)發(fā)生、鞘磷脂形成、軸突生長(zhǎng)等,而在腦外傷早期的病理發(fā)展中有損傷作用[6-7]。小膠質(zhì)細(xì)胞激活后可以促進(jìn)MMPs表達(dá),對(duì)局部多巴胺能神經(jīng)元膜的結(jié)構(gòu)和功能產(chǎn)生損害,使多巴胺能神經(jīng)元變性、壞死[8-10]。
他汀類藥物作為HMG-CoA抑制劑是最重要的降脂藥物之一,廣泛用于心腦血管疾病中抗動(dòng)脈粥樣硬化的治療[11-12]。近年大量研究發(fā)現(xiàn)其除降脂作用外,還包括抗炎、免疫調(diào)節(jié)、抗氧化等,因而在治療免疫介導(dǎo)的疾病如多發(fā)性硬化、器官移植排斥等方面具有令人矚目的應(yīng)用前景。本課題組近年來(lái)研究已經(jīng)證實(shí)阿托伐他汀對(duì)腦外傷模型的小鼠具有抗炎作用[13-14],但對(duì)究竟如何起到抗炎作用仍未知。
本研究觀察到小鼠TBI后給予阿托伐他汀可以減少創(chuàng)傷灶周圍的小膠質(zhì)細(xì)胞激活,降低TNF-α和MMP-9,證實(shí)阿托伐他汀對(duì)于TBI后小膠質(zhì)細(xì)胞具有抑制激活的作用,從而影響其參與的神經(jīng)疾病免疫反應(yīng),這可能是阿托伐他汀在TBI中抗炎的機(jī)制之一。但阿托伐他汀究竟是如何影響小膠質(zhì)細(xì)胞激活,對(duì)于小膠質(zhì)細(xì)胞激活極化是否有影響仍待進(jìn)一步研究。
參考文獻(xiàn)
[1]Cope EC,Morris DR,Levenson CW.Improving treatments and outcomes:an emergingrole for zinc in traumatic brain injury[J].Nutr Rev,2012,70(7):410-413.doi:10.1111/j.1753-4887.2012.00486.x.
[2]Thurman DJ,Alverson C,Dunn KA,et al.Traumatic brain injury in the United States:A public health perspective[J].J Head Trauma Rehabil,1999,14(6):602-615.
[3]Loane DJ,Byrnes KR.Role of microglia in neurotrauma[J].Neurotherapeutics,2010,7(4):366-377.doi:10.1016/j.nurt.2010.07.002.
[4]McIntosh TK,Vink R,Noble L,et al.Traumatic brain injury in the rat:characterization of a lateral fluid-percussion model[J].Neuroscience,1989,28(1):233-244.
[5]Blennow K,Hardy J,Zetterberg H.The neuropathology and neurobiology of traumatic brain injury[J].Neuron,2012,76(5):886-899.doi:10.1016/j.neuron.2012.11.021.
[6]Reinhard SM,Razak K,Ethell IM.A delicate balance:role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders[J].Front Cell Neurosci,2015,9:280.doi:10.3389/fncel.2015.00280.eCollection 2015.
[7]Egashira Y,Zhao H,Hua Y,et al.White Matter Injury After Subarachnoid Hemorrhage:Role of Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9[J].Stroke,2015,46(10):2909-2915.doi:10.1161/STROKEAHA.115.010351.
[8]Mun-Bryce S,Lukes A,Wallace J,et al.Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation[J].Brain Res,2002,933(1):42-49.
[9]Rosenberg GA,Cunningham LA,Wallace J,et al.Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain:activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures[J].Brain Res,2001,893(1/2):104-112.
[10]del Zoppo GJ,Milner R,Mabuchi T,et al.Microglial activation and matrix protease generation duringfocal cerebral ischemia[J].Stroke,2007,38(2 Suppl):646-651.
[11]Zhu FQ,Chen L,Zhu JH.Influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke[J].Chin J Contemp Neurol Neurosurg,2015,15(1):43-47.[朱飛奇,陳略,朱瑾華.黃連素聯(lián)合阿托伐他汀對(duì)急性缺血性卒中患者血清超敏C-反應(yīng)蛋白和脂肪細(xì)胞型脂肪酸結(jié)合蛋白水平的影響[J].中國(guó)現(xiàn)代神經(jīng)疾病雜志,2015,15(1):43-47]. doi:10.3969/j.issn.1672-6731.2015.01.010.
[12]Zheng XD,Li XQ,Zhang JH,et al.Preliminary study on the efficacy and safety of atorvastatin in northern Han patients with acute ischemic cerebrovascular disease[J].Med J Chin PLA,2015,40(7):519-525.[鄭雪丹,李曉秋,張景華,等.阿托伐他汀對(duì)北方漢族人群急性缺血性腦血管病有效性和安全性的初步研究[J].解放軍醫(yī)學(xué)雜志,2015,40(7):519-525].doi:10.11855/j.issn.0577-7402.2015.07.02.
[13]Li T,WangD,Tian Y,et al.Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats[J].J Neurol Sci,2014,341(1/2):88-96.doi:10.1016/j.jns.2014.04.009.
[14]Jin WP,Wang B,Zhao ZL,et al.Effects of atorvastatin on endothelial progenitor cells and neural function in rats with traumatic brain injury[J].Tianjin Med J,2013,41(5):465-467.[金衛(wèi)篷,王彬,趙子龍,等.阿托伐他汀對(duì)顱腦損傷大鼠內(nèi)皮祖細(xì)胞和神經(jīng)功能的影響[J].天津醫(yī)藥,2013,41(5):465-467].
(2015-11-01收稿2015-11-30修回)
(本文編輯魏杰)
Effects of atorvastatin on the microglia activation after traumatic brain injury
YU Gongjie1,SUN Dongdong1,ZENG Yong1,GAO Weiwei1,CHEN Siqin2,ZHANG Jianning1
1 Department of Neurosurgery,Tianjin Medical University General Hospital,Tianjin Neurological Institute,Tianjin 300052,China;2 Research Center of Basic Medical Sciences,Tianjin Medical University Corresponding AuthorE-mail:jianningzhang@hotmail.com
Abstract:ObjectiveTo observe the effects of atorvastatin on the microglia activation after traumatic brain injury (TBI).MethodsSixty adult male C57/BL6 mice were randomly divided into sham group,atorvastatin group and saline group,20 mice for each group.The atorvastatin group and saline group were given hydraulic combat to establish TBI mouse model.The shame group underwent the same surgical procedure without being exposed to percussion injury.The atorvastatin group was treated with atorvastatin(orally,1 mg/kg)1 h after TBI and for 7 consecutive days.The saline group was given saline orally.The expression of microglia(Iba-1+)at the 1st,3rd,and 7th day after TBI and matrix metalloproteinase-9(MMP-9)around the lesion at the 3rd day after TBI were detected by immunohistochemical staining.Tumor necrosis factor(TNF)-α was detected by Western blot assay at the 3rd day after TBI.ResultsThe positive expression of Iba-1+microgliawas significantly decreased in atorvastatin group than that of saline group at the 1st,3rd,and 7th day after TBI(80.00±7.44 vs.118.40± 6.65,85.60±10.87 vs.189.00±7.51,69.40±5.54 vs.102.40±10.89,P<0.05).The positive expression of MMP-9 was significantly decreased in atorvastatin group compared with that of saline group at the 3rd day after TBI(86.80±8.40 vs.133.80± 8.46,P<0.05).Results of Western blot assay showed that the positive expression of TNF-α was significantly decreased in astorvastatin group than that of saline group at the 3rd day after TBI(0.64±0.01 vs.0.97±0.02,P<0.05).ConclusionAtorvastatin can reduce inflammation factor by influencingthe microgliaactivation after TBI in mice.
Key words:craniocerebral trauma;microglia;matrix metalloproteinase 9;tumor necrosis factor-alpha;Atorvastatin
中圖分類號(hào):R651.1+5
文獻(xiàn)標(biāo)志碼:A
DOI:10.11958/20150279
基金項(xiàng)目:國(guó)家自然科學(xué)基金面上項(xiàng)目(81271361);國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目(81330029)
作者單位:1天津醫(yī)科大學(xué)總醫(yī)院神經(jīng)外科,天津市神經(jīng)病學(xué)研究所(郵編300052);2天津醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)研究中心轉(zhuǎn)化腫瘤實(shí)驗(yàn)室
作者簡(jiǎn)介:郁龔杰(1989),男,碩士在讀,主要從事顱腦外傷的研究
通訊作者E-mail:jianningzhang@hotmail.com